Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:19:37 ON 20 NOV 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:19:48 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10594960 generic.str



chain nodes :
15 16 17 18 19 25 26 27 28 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 20 21 22 23 24
chain bonds :

```
13-15  15-16  15-29  16-17  17-18  17-25  18-19  18-31  19-20  24-30  25-26  26-27
26-28
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  8-11  9-10  9-14  11-12  12-13
13-14  20-21  20-24  21-22  22-23  23-24
exact/norm bonds :
5-7  6-10  7-8  8-9  8-11  9-10  9-14  11-12  12-13  13-14  15-16  15-29  16-17
18-19  18-31  19-20  20-21  20-24  21-22  22-23  23-24  24-30
exact bonds :
13-15  17-18  17-25  25-26  26-27  26-28
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:CLASS  26:CLASS  27:CLASS
 28:CLASS  29:CLASS  30:CLASS  31:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:20:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1
```

```
=> s l1 sss ful
FULL SEARCH INITIATED 14:20:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       31 TO ITERATE

100.0% PROCESSED       31 ITERATIONS                                15 ANSWERS
SEARCH TIME: 00.00.01

L3           15 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 14:20:16 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008  VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008  (20081119/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4           8 L3

=> d l4 1-8 ibib abs hitstr

L4   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2007:1022710  CAPLUS
DOCUMENT NUMBER:         147:357234
TITLE:                   Composition containing amidine derivatives or
                         carboxamide derivatives and steroids, as a medicament
INVENTOR(S):             Pignol, Bernadette; Auvin, Serge; Bigg, Dennis;
                         Chabrier de Lassauniere, Pierre-Etienne
PATENT ASSIGNEE(S):      Societe de Conseils de Recherches et d'Applications
                         Scientifiques (S.C.R.A.S.), Fr.
SOURCE:                  PCT Int. Appl., 42pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                French
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007101937	A1	20070913	WO 2007-FR390	20070306
FR 2898274	A1	20070914	FR 2006-2000	20060307
FR 2898274	B1	20081003		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: FR 2006-2000 A 20060307

OTHER SOURCE(S): MARPAT 147:357234

AB The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative (Markush included) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein the composition is suitable for the preparation of a medicament.

Compound

preparation is included.

IT 339007-48-6 339007-48-6D, salts 339007-76-0 339007-76-0D, salts 742104-24-1 742104-24-1D, salts 866006-13-5 866006-13-5D, salts 866006-14-6 866006-14-6D, salts 866006-16-8 866006-16-8D, salts 866006-17-9 866006-17-9D, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amidine derivative or carboxamide derivative combination with steroid for therapeutic)

RN 339007-48-6 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-48-6 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-76-0 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2R,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-76-0 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2R,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-13-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-13-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-14-6 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-14-6 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-16-8 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-16-8 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:452302 CAPLUS
DOCUMENT NUMBER: 147:64455
TITLE: A novel dual inhibitor of calpains and lipid peroxidation (BN82270) rescues the cochlea from sound trauma
AUTHOR(S): Wang, Jing; Pignol, Bernadette; Chabrier, Pierre-Etienne; Saido, Takaomi; Lloyd, Ruth; Tang, Yong; Lenoir, Marc; Puel, Jean-Luc
CORPORATE SOURCE: Laboratoire de Physiopathologie et Therapie des Deficits Sensoriels et Moteurs, INSERM U583, Montpellier, Fr.
SOURCE: Neuropharmacology (2007), 52(6), 1426-1437
CODEN: NEPHBW; ISSN: 0028-3908
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Free radical and calcium buffering mechanisms are implicated in cochlear cell damage that has been induced by sound trauma. Thus in this study we evaluated the therapeutic effect of a novel dual inhibitor of calpains and of lipid peroxidn. (BN 82270) on the permanent hearing and hair cell loss induced by sound trauma. Perfusion of BN 82270 into the scala tympani of the guinea pig cochlea prevented the formation of calpain-cleaved fodrin, translocation of cytochrome c, DNA fragmentation and hair cell degeneration caused by sound trauma. This was confirmed by functional tests in vivo, showing a clear dose-dependent reduction of permanent hearing loss (ED50 = 4.07 μM) with almost complete protection at 100 μM. Furthermore, BN82270 still remained effective even when applied onto the round window membrane after sound trauma had occurred, within a therapeutic window of 24 h. This indicates that BN 82270 may be of potential therapeutic value in treating the cochlea after sound trauma.

IT 742104-24-1, BN 82270
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dual inhibitor of calpains and lipid peroxidn. (BN82270) rescues the cochlea from sound trauma)
RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:325817 CAPLUS
DOCUMENT NUMBER: 146:372657
TITLE: Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. [Erratum to document cited in CA146:075148]
AUTHOR(S): Pignol, Bernadette; Auvin, Serge; Carre, Denis; Marin, Jean-Gregoire; Chabrier, Pierre-Etienne
CORPORATE SOURCE: Department of Neurobiology, Ipsen Research Laboratories, Les Ulis, Fr.
SOURCE: Journal of Neurochemistry (2007), 100(5), 1430
CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB On page 1224, right column, second full paragraph, line 2, "BHT-PD150606" should read: "BHT+PD150606". On page 1224, right column, second full paragraph, line 2, "BHT++calpeptin" should read: "BHT+calpeptin". On page 1224, right column, second full paragraph, line 3, "4-hydroxydiphenylamine++Z-Leu-Leu-H" should read: "4-hydroxydiphenylamine+Z-Leu-Leu-H". On page 1224, right column, second full paragraph, line 3, "BHT-Z-Leu-Leu-H" should read: "BHT+Z-Leu-Leu-H".
IT 339007-47-5, BN 82204 742104-24-1, BN 82270
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of calpain inhibitors and antioxidants in combination or single BN 82204 and its pro-drug BN 82270 with multiple activities to prevent cell necrosis (Erratum))
RN 339007-47-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1135981 CAPLUS
DOCUMENT NUMBER: 146:75148
TITLE: Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270
AUTHOR(S): Pignol, Bernadette; Auvin, Serge; Carre, Denis; Marin, Jean-Gregoire; Chabrier, Pierre-Etienne
CORPORATE SOURCE: Department of Neurobiology, Ipsen Research Laboratories, Les Ulis, Fr.
SOURCE: Journal of Neurochemistry (2006), 98(4), 1217-1228
CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Cell death is a common feature observed in neurodegenerative disorders, and is often associated with calpain activation and overprodn. of reactive oxygen species (ROS). This study investigated the use of calpain inhibitors and antioxidants in combination to protect cells against necrosis. Maitotoxin (MTX), which induces a massive influx of calcium, was used to provoke neuronal cell death. This toxin increased, in a concentration-dependent manner, both calpain activity and ROS formation. Calpain inhibitors or antioxidants inhibited MTX-induced necrosis only marginally (below 20%), whereas their association protected against cell death by 40-66% in a synergistic manner. BN 82204, which possesses both calpain-cathepsin L inhibitory and antioxidant properties, and its acetylated pro-drug BN 82270, totally protected cells at 100 μM. The pro-drug BN 82270, which had better cell penetration, was twice as effective as the active principle BN 82204 in protecting glioma C6 or neuroblastoma SHSY5Y cells against death. These results suggest the potential therapeutic relevance of using a single mol. with multiple activities (cysteine protease inhibitor/antioxidant), and warrant further in vivo investigations in models of neuronal disorders.

IT 339007-47-5, BN 82204 742104-24-1, BN 82270
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of calpain inhibitors and antioxidants in combination or single BN 82204 and its pro-drug BN 82270 with multiple activities to prevent cell necrosis)

RN 339007-47-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:583794 CAPLUS
DOCUMENT NUMBER: 145:116788
TITLE: Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression
AUTHOR(S): Fareed, Moin U.; Evenson, Amy R.; Wei, Wei; Menconi, Michael; Poylin, Vitaliy; Petkova, Victoria; Pignol, Bernadette; Hasselgren, Per-Olof
CORPORATE SOURCE: Department of Surgery, Harvard Medical School, Boston, MA, USA
SOURCE: American Journal of Physiology (2006), 290(6, Pt. 2), R1589-R1597
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Muscle wasting in sepsis is a significant clin. problem because it results in muscle weakness and fatigue that may delay ambulation and increase the risk for thromboembolic and pulmonary complications. Treatments aimed at preventing or reducing muscle wasting in sepsis, therefore, may have important clin. implications. Recent studies suggest that sepsis-induced muscle proteolysis may be initiated by calpain-dependent release of myofilaments from the sarcomere, followed by ubiquitination and degradation of the myofilaments by the 26S proteasome. In the present expts., treatment of rats with one of the calpain inhibitors calpeptin or BN82270 inhibited protein breakdown in muscles from rats made septic by cecal ligation and puncture. The inhibition of protein breakdown was not accompanied by reduced expression of the ubiquitin ligases atrogin-1/MAFbx and MuRF1, suggesting that the ubiquitin-proteasome system is regulated independent of the calpain system in septic muscle. When incubated muscles were treated in vitro with calpain inhibitor, protein breakdown rates and calpain activity were reduced, consistent with a direct effect in skeletal muscle. Addnl. expts. suggested that the effects of BN82270 on muscle

protein breakdown may, in part, reflect inhibited cathepsin L activity, in addition to inhibited calpain activity. When cultured myoblasts were transfected with a plasmid expressing the endogenous calpain inhibitor calpastatin, the increased protein breakdown rates in dexamethasone-treated myoblasts were reduced, supporting a role of calpain activity in atrophying muscle. The present results suggest that treatment with calpain inhibitors may prevent sepsis-induced muscle wasting.

IT 742104-24-1, BN 82270
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression)

RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1075636 CAPLUS

DOCUMENT NUMBER: 143:339689

TITLE: Use of a phenothiazine derivative for preventing and/or treating hearing loss

INVENTOR(S): Pignol, Bernadette; Puel, Jean-Luc; Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Wang, Jing

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.C.R.A.S., Fr.

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092345	A1	20051006	WO 2005-FR713	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2867979	A1	20050930	FR 2004-3203	20040329
FR 2867979	B1	20060630		

CA 2560988	A1	20051006	CA 2005-2560988		20050325
EP 1732567	A1	20061220	EP 2005-744629		20050325
EP 1732567	B1	20081008			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1933840	A	20070321	CN 2005-80009139		20050325
JP 2007530640	T	20071101	JP 2007-505576		20050325
US 20080275034	A1	20081106	US 2006-594960		20060929
PRIORITY APPLN. INFO.:			FR 2004-3203	A	20040329
			FR 2004-6404	A	20040614
			WO 2005-FR713	W	20050325

OTHER SOURCE(S): MARPAT 143:339689

GI



I

AB The invention discloses the use of a phenothiazine derivative I (R = H, alkyl, aralkyl, etc.) for preparing a medicine for preventing and/or treating hearing loss.

IT 339007-47-5 339007-47-5D, derivs. 742104-24-1
866006-13-5 866006-13-5D, derivs. 866006-14-6
866006-14-6D, derivs. 866006-15-7 866006-15-7D
, derivs. 866006-16-8 866006-16-8D, derivs.
866006-17-9 866006-17-9D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenothiazine derivs. for prevention and/or treatment of hearing loss)

RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 742104-24-1 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-13-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-13-5 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-14-6 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-14-6 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-15-7 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-15-7 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-16-8 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-16-8 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2S,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866006-17-9 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1R)-3-methyl-1-[[[(2R,3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:498592 CAPLUS
DOCUMENT NUMBER: 141:207514
TITLE: Novel dual inhibitors of calpain and lipid

peroxidation

AUTHOR(S): Auvin, Serge; Pignol, Bernadette; Navet, Edith; Pons, Dominique; Marin, Jean-G.; Bigg, Dennis; Chabrier, Pierre-E.

CORPORATE SOURCE: Department of Medicinal Chemistry, Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91966, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3825-3828
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:207514

GI



I

AB A series of mols. I (R1 = phenothiazin-1-yl, phenothiazin-2-yl, 1-benzyl-5-indolinylamino, etc., R2 = H; R1 = phenothiazin-2-yl, R2 = MeCO) with dual inhibitory activities on calpain and lipid peroxidn. were synthesized. These hybrid compds. were built on the calpain pharmacophore 2-hydroxytetrahydrofuran linked to a set of antioxidants via a L-leucine linker. I (R1 = phenothiazin-2-yl, R2 = MeCO), the most potent in cellular calpain and lipid peroxidn. inhibitions, provided effective protection against glial cell death induced by maitotoxin.

IT 339007-47-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (peptidyl)(hydroxy)tetrahydrofurans as dual inhibitors of calpain and lipid peroxidn.)

RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 742104-24-1P, BN 82270
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (peptidyl)(hydroxy)tetrahydrofurans as dual inhibitors of calpain and lipid peroxidn.)

RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-

3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:338525 CAPLUS
DOCUMENT NUMBER: 134:353248
TITLE: Novel heterocyclic compounds and their use as medicines
INVENTOR(S): Auvin, Serge; Chabrier De Lassauniere, Pierre-Etienne
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032654	A2	20010510	WO 2000-FR3067	20001103
WO 2001032654	A3	20010927		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2800737	A1	20010511	FR 1999-13858	19991105
FR 2800737	B1	20060630		
FR 2809398	A1	20011130	FR 2000-6535	20000523
FR 2809398	B3	20020726		
CA 2389685	A1	20010510	CA 2000-2389685	20001103
BR 2000015315	A	20020625	BR 2000-15315	20001103
EP 1233962	A2	20020828	EP 2000-974646	20001103
EP 1233962	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003183	A2	20030228	HU 2002-3183	20001103
HU 2002003183	A3	20060228		
JP 2003513092	T	20030408	JP 2001-534805	20001103
NZ 518420	A	20040227	NZ 2000-518420	20001103
AU 781551	B2	20050526	AU 2001-12871	20001103
RU 2260009	C2	20050910	RU 2002-114696	20001103
AT 318809	T	20060315	AT 2000-974646	20001103
EP 1661564	A1	20060531	EP 2005-77194	20001103

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

PT	1233962	T	20060731	PT	2000-974646	20001103
ES	2259617	T3	20061016	ES	2000-974646	20001103
CN	1317278	C	20070523	CN	2000-815926	20001103
US	6747024	B1	20040608	US	2002-111994	20020430
NO	2002002088	A	20020502	NO	2002-2088	20020502
MX	2002PA04442	A	20020902	MX	2002-PA4442	20020503
IN	2002MN00604	A	20050304	IN	2002-MN604	20020513
HK	1052706	A1	20070928	HK	2003-105058	20030714
US	20040180936	A1	20040916	US	2004-803387	20040316
AU	2005203713	A1	20050915	AU	2005-203713	20050818

PRIORITY APPLN. INFO.:

FR	1999-13858	A 19991105
FR	2000-6535	A 20000523
EP	2000-974646	A3 20001103
WO	2000-FR3067	W 20001103
US	2002-111994	A3 20020430

OTHER SOURCE(S): MARPAT 134:353248

AB Novel heterocyclic derivs. which have calpain inhibiting and/or reactive oxygen species trapping activity (no data) are reported. Thus, (R)-Trolox was treated with (S)-2-aminobutyrolactone hydrochloride, followed by DIBAL reduction to give (2R)-6-hydroxy-N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxamide.

IT 339007-47-5P 339007-48-6P 339007-52-2P
339007-53-3P 339007-54-4P 339007-55-5P
339007-56-6P 339007-57-7P 339007-76-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel heterocyclic compds. as calpain inhibitors and trapping agents for reactive oxygen species)

RN 339007-47-5 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-3-methyl-1-[[[(3S)-tetrahydro-2-hydroxy-3-furanyl]amino]carbonyl]butyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-48-6 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-52-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-53-3 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-54-4 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(benzoyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-55-5 CAPLUS
CN Benzeneacetic acid, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-56-6 CAPLUS
CN L-Phenylalanine, N,N-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-57-7 CAPLUS
CN 4-Morpholinecarboxylic acid, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-76-0 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2R,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	56.08	234.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

STN INTERNATIONAL LOGOFF AT 14:35:45 ON 20 NOV 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families

```
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11  FEB 02  Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATEM
 NEWS 12  FEB 02  GENBANK enhanced with SET PLURALS and SET SPELLING

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:10:15 ON 04 FEB 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 14:10:37 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 FEB 2009  HIGHEST RN 1100396-01-7
DICTIONARY FILE UPDATES:   3 FEB 2009  HIGHEST RN 1100396-01-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10594960 substituent.str
```



chain nodes :
1 2 3 4 10 11 12 13 14 15 16 17 18
ring nodes :
5 6 7 8 9
chain bonds :
1-2 2-3 2-14 3-4 3-18 4-5 6-10 10-11 11-12 11-13 14-15 15-16 15-17
ring bonds :
5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-2 3-4 3-18 4-5 5-6 5-9 6-7 6-10 7-8 8-9 10-11 11-13
exact bonds :
2-3 2-14 11-12 14-15 15-16 15-17

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:10:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED        9 ITERATIONS                                 5 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            9 TO      360
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 14:11:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      157 TO ITERATE

100.0% PROCESSED      157 ITERATIONS                                88 ANSWERS
SEARCH TIME: 00.00.01

L3           88 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  185.88     186.10

FILE 'CAPLUS' ENTERED AT 14:11:08 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Feb 2009  VOL 150 ISS 6
FILE LAST UPDATED: 3 Feb 2009  (20090203/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4           20 L3
```

```
=> s l4 and calpain
          6175 CALPAIN
          1323 CALPAINS
          6326 CALPAIN
                 (CALPAIN OR CALPAINS)
L5          16 L4 AND CALPAIN

=> s l5 and (py<2005 or ay<2005 or pry<2005)
      25138666 PY<2005
       5122214 AY<2005
       4598644 PRY<2005
L6          10 L5 AND (PY<2005 OR AY<2005 OR PRY<2005)

=> d l6 1-10 ibib abs hitstr

L6   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:697982  CAPLUS
DOCUMENT NUMBER:          149:54264
TITLE:                    Preparation of 2-hydroxytetrahydrofuran peptide
                          derivatives for use as medicaments
INVENTOR(S):              Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne
PATENT ASSIGNEE(S):       Societe de Conseils de Recherches et d'Applications
                          Scientifiques (S.C.R.A.S.), Fr.
SOURCE:                   U.S., 20pp., Cont.-in-part of U.S. Ser. No. 532,731.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 7384933            B2    20080610    US 2005-115480          20050427 <--
     US 20050222045        A1    20051006
     FR 2863268            A1    20050610    FR 2003-14368           20031209 <--
     FR 2863268            B1    20060224
     WO 2005056551         A2    20050623    WO 2004-FR3147          20041208 <--
     WO 2005056551         A3    20050811
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     US 20060166893        A1    20060727    US 2005-532731          20050426 <--
     US 7465721            B2    20081216
PRIORITY APPLN. INFO.:                       FR 2003-14368       A   20031209 <--
                                             WO 2004-FR3147      A   20041208 <--
                                             US 2005-532731      A2  20050426
OTHER SOURCE(S):          MARPAT 149:54264
GI
```



I

AB The invention relates to hydroxytetrahydrofuran derivs. I [R1, R2, R4, R5, R6 are independently H, halo, OH, alkyl, alkoxy, cyano, nitro, amino or acylamino groups; R3 is H, alkyl, acyl, or carbalkoxy; W is a bond, CH2CH2, CH:CH, O, S, NH or alkylimino; X is CO, Y-CO, O-Y-CO (Y is alkylene or haloalkylene), NH, alkylimino, acyl, or carbalkoxy; AA is NR7(CH2)3CHR8CO (R7, R8 are H or alkyl), a natural amino acid, including a natural amino acid whose side chain carries a protected reactive chemical function; n is 2 or 3; R is H, alkyl, or alkanoyl] which have calpain-inhibiting activity and/or activity which traps reactive oxygen species and are useful for treating inflammatory and immunol. diseases, cardiovascular and cerebrovascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases. Thus, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N1-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide, prepared by a multistep sequence which starts with reaction of Cbz-protected L-leucine with (S)-2-amino-4-butyrolactone hydrobromide, showed IC50 ≤ 5 μM in the human calpain I inhibition assay.

IT 853208-13-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydrofuran peptide derivs. for use as medicaments)

RN 853208-13-6 CAPLUS

CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1075636 CAPLUS

DOCUMENT NUMBER: 143:339689

TITLE: Use of a phenothiazine derivative for preventing and/or treating hearing loss

INVENTOR(S): Pignol, Bernadette; Puel, Jean-Luc; Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Wang, Jing

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.C.R.A.S., Fr.

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092345	A1	20051006	WO 2005-FR713	20050325 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2867979	A1	20050930	FR 2004-3203	20040329 <--
FR 2867979	B1	20060630		
CA 2560988	A1	20051006	CA 2005-2560988	20050325 <--
EP 1732567	A1	20061220	EP 2005-744629	20050325 <--
EP 1732567	B1	20081008		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1933840	A	20070321	CN 2005-80009139	20050325 <--
JP 2007530640	T	20071101	JP 2007-505576	20050325 <--
US 20080275034	A1	20081106	US 2006-594960	20060929 <--

PRIORITY APPLN. INFO.:
FR 2004-3203 A 20040329 <--
FR 2004-6404 A 20040614 <--
WO 2005-FR713 W 20050325

OTHER SOURCE(S): MARPAT 143:339689
GI



I

AB The invention discloses the use of a phenothiazine derivative I (R = H, alkyl, aralkyl, etc.) for preparing a medicine for preventing and/or treating hearing loss.

IT 742104-24-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenothiazine derivs. for prevention and/or treatment of hearing loss)

RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:492131 CAPLUS
DOCUMENT NUMBER: 143:44075
TITLE: Preparation of peptidyl 3-aminotetrahydro-2-furanol derivatives for use as drugs
INVENTOR(S): Auvin, Serge; Chabrier De Lassauniere, Pierre Etienne
PATENT ASSIGNEE(S): Societe De Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SOURCE: Fr. Demande, 53 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2863268	A1	20050610	FR 2003-14368	20031209 <--
FR 2863268	B1	20060224		
CA 2548448	A1	20050623	CA 2004-2548448	20041208 <--
WO 2005056551	A2	20050623	WO 2004-FR3147	20041208 <--
WO 2005056551	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1701974	A2	20060920	EP 2004-816363	20041208 <--
EP 1701974	B1	20080326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007513929	T	20070531	JP 2006-543581	20041208 <--
AT 390437	T	20080415	AT 2004-816363	20041208 <--
ES 2304639	T3	20081016	ES 2004-816363	20041208 <--
US 20060166893	A1	20060727	US 2005-532731	20050426 <--
US 7465721	B2	20081216		
US 7384933	B2	20080610	US 2005-115480	20050427 <--
US 20050222045	A1	20051006		

PRIORITY APPLN. INFO.:
FR 2003-14368 A 20031209 <--
WO 2004-FR3147 W 20041208 <--
US 2005-532731 A2 20050426

OTHER SOURCE(S): MARPAT 143:44075
GI



I

AB The invention relates to peptide derivs. I [A is (un)substituted carbazolyl, dibenzo[b,f]azepinyl or 10,11-dihydro derivs., phenoxazinyl, phenothiazinyl or phenazinyl; X is CO, Y-CO, O-Y-CO or NR1-Y-CO; Y is alkylene or haloalkylene; R, R1 are independently H, alkyl or acyl; AA is a natural amino acid or derivative; n is 2,3] or their salts which inhibit calpains and lipid peroxidn. and can be used to treat inflammatory, immunol., cardiovascular and other diseases. Thus, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N1-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide was prepared by a multistep procedure involving reactions of Cbz-L-Leucine (Cbz = benzyloxycarbonyl), (S)-2-amino-4-butyrolactone hydrobromide, and 2-acetylphenothiazine and treatment with 2N HCl. The product showed IC50 < 5 μM for inhibition of human calpain I.

IT 853208-13-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyl aminotetrahydrofuranol derivs. for use as drugs)

RN 853208-13-6 CAPLUS

CN L-Leucinamide, N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:498592 CAPLUS

DOCUMENT NUMBER: 141:207514

TITLE: Novel dual inhibitors of calpain and lipid peroxidation

AUTHOR(S): Auvin, Serge; Pignol, Bernadette; Navet, Edith; Pons, Dominique; Marin, Jean-G.; Bigg, Dennis; Chabrier, Pierre-E.

CORPORATE SOURCE: Department of Medicinal Chemistry, Ipsen Research Laboratories, Institut Henri Beaufour, Les Ulis, 91966, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3825-3828
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:207514
GI



I

AB A series of mols. I (R1 = phenothiazin-1-yl, phenothiazin-2-yl, 1-benzyl-5-indolinylamino, etc., R2 = H; R1 = phenothiazin-2-yl, R2 = MeCO) with dual inhibitory activities on calpain and lipid peroxidn. were synthesized. These hybrid compds. were built on the calpain pharmacophore 2-hydroxytetrahydrofuran linked to a set of antioxidants via a L-leucine linker. I (R1 = phenothiazin-2-yl, R2 = MeCO), the most potent in cellular calpain and lipid peroxidn. inhibitions, provided effective protection against glial cell death induced by maitotoxin.

IT 742104-24-1P, BN 82270
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (peptidyl)(hydroxy)tetrahydrofurans as dual inhibitors of calpain and lipid peroxidn.)

RN 742104-24-1 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:338525 CAPLUS
DOCUMENT NUMBER: 134:353248
TITLE: Novel heterocyclic compounds and their use as medicines
INVENTOR(S): Auvin, Serge; Chabrier De Lassauniere, Pierre-Etienne
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001032654	A2	20010510	WO 2000-FR3067	20001103 <--
WO 2001032654	A3	20010927		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2800737	A1	20010511	FR 1999-13858	19991105 <--
FR 2800737	B1	20060630		
FR 2809398	A1	20011130	FR 2000-6535	20000523 <--
FR 2809398	B3	20020726		
CA 2389685	A1	20010510	CA 2000-2389685	20001103 <--
BR 2000015315	A	20020625	BR 2000-15315	20001103 <--
EP 1233962	A2	20020828	EP 2000-974646	20001103 <--
EP 1233962	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003183	A2	20030228	HU 2002-3183	20001103 <--
HU 2002003183	A3	20060228		
JP 2003513092	T	20030408	JP 2001-534805	20001103 <--
NZ 518420	A	20040227	NZ 2000-518420	20001103 <--
AU 781551	B2	20050526	AU 2001-12871	20001103 <--
RU 2260009	C2	20050910	RU 2002-114696	20001103 <--
AT 318809	T	20060315	AT 2000-974646	20001103 <--
EP 1661564	A1	20060531	EP 2005-77194	20001103 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PT 1233962	T	20060731	PT 2000-974646	20001103 <--
ES 2259617	T3	20061016	ES 2000-974646	20001103 <--
CN 1317278	C	20070523	CN 2000-815926	20001103 <--
US 6747024	B1	20040608	US 2002-111994	20020430 <--
NO 2002002088	A	20020502	NO 2002-2088	20020502 <--
MX 2002004442	A	20020902	MX 2002-4442	20020503 <--
IN 2002MN00604	A	20050304	IN 2002-MN604	20020513 <--
HK 1052706	A1	20070928	HK 2003-105058	20030714 <--
US 20040180936	A1	20040916	US 2004-803387	20040316 <--
AU 2005203713	A1	20050915	AU 2005-203713	20050818 <--
PRIORITY APPLN. INFO.:			FR 1999-13858 A	19991105 <--
			FR 2000-6535 A	20000523 <--
			EP 2000-974646 A3	20001103 <--
			WO 2000-FR3067 W	20001103 <--
			US 2002-111994 A3	20020430 <--

OTHER SOURCE(S): MARPAT 134:353248

AB Novel heterocyclic derivs. which have calpain inhibiting and/or reactive oxygen species trapping activity (no data) are reported. Thus, (R)-Trolox was treated with (S)-2-aminobutyrolactone hydrochloride, followed by DIBAL reduction to give (2R)-6-hydroxy-N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxamide.

IT 339007-48-6P 339007-52-2P 339007-53-3P
339007-55-5P 339007-56-6P 339007-76-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel heterocyclic compds. as calpain inhibitors and trapping agents for reactive oxygen species)

RN 339007-48-6 CAPLUS

CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2S,3S)-2-

(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-52-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-53-3 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-55-5 CAPLUS
CN Benzeneacetic acid, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-56-6 CAPLUS
CN L-Phenylalanine, N,N-dimethyl-, (3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(10H-phenothiazin-2-ylcarbonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 339007-76-0 CAPLUS
CN 10H-Phenothiazine-2-carboxamide, N-[(1S)-1-[[[(2R,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:233912 CAPLUS
DOCUMENT NUMBER: 130:252373
TITLE: Preparation and formulation of O-containing heterocyclic derivatives as cysteine protease inhibitors
INVENTOR(S): Usui, Yoshihiro; Masuda, Hirokazu; Ando, Naoko; Nakao, Akira; Ando, Ryoichi; Yoshii, Narihiko; Saito, Ken-ichi
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan
SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916761	A1	19990408	WO 1998-JP4420	19980930 <--
W: CA, CN, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11171881	A	19990629	JP 1998-277586	19980930 <--

PRIORITY APPLN. INFO.: JP 1997-266034 A 19970930 <--
OTHER SOURCE(S): MARPAT 130:252373
GI



I

AB The title compds. I [R1 represents optionally substituted C6-14 aryl or an optionally substituted heterocycle residue; R2 represents hydrogen or C1-10 alkyl optionally substituted by C6-14 aryl; R3 represents hydrogen or R4CO (R4 represents C1-10 alkyl); and A represents C1-3 alkylene optionally substituted by C1-3 alkyl] are prepared I are useful as cysteine protease inhibitors excellent in oral absorbability, migration to tissues, and can easily pass through the cell membrane, etc. (3S)-3-[(S)-2-(4,6-dimethoxy-2-pyrimidinyl)amino-4-methylvalerylamino]-2-tetrahydrofuranol in vitro showed IC50 of 1.27 μM against calpain.

IT 221683-02-9P 221683-09-6P 221683-12-1P
221683-20-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of O-containing heterocyclic derivs. as cysteine protease inhibitors)

RN 221683-02-9 CAPLUS
CN Pentanamide, N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(4,6-dimethoxy-2-pyrimidinyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221683-09-6 CAPLUS

CN Pentanamide, N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[[2-nitro-4-(trifluoromethyl)phenyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221683-12-1 CAPLUS
CN Pentanamide, N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-(2-benzoxazolylamino)-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 221683-20-1 CAPLUS
CN Pentanamide, N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(2-nitrophenyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:246624 CAPLUS
DOCUMENT NUMBER: 129:32318
ORIGINAL REFERENCE NO.: 129:6761a,6764a
TITLE: Cataract curative medicine.
INVENTOR(S): Watanabe, Toshiaki; Yoshii, Shigehiko; Saito, Kenichi; Ando, Ryoichi

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 74 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10101557	A	19980421	JP 1997-197216	19970723 <--
PRIORITY APPLN. INFO.:			JP 1996-208540 A	19960807 <--

OTHER SOURCE(S): MARPAT 129:32318
GI For diagram(s), see printed CA Issue.
AB The cataract curative medicine has an effective component of structure (I), its salt, solvate, or hydrate, where R1 is R4-CO-, R4-O-CO-, or R4-SO2- (R4: C1-20 alkyl), R2 is C1-C6 alkyl, R3 is H or R5-CO- (R5: C1-10 alkyl), and A is C1-3 alkylene. Thus, 998 mg N-phenylsulfonyl-L-leucine was react with 6 mL SO2Cl2 and 443 mg homoserine lactone to give (S)-3-[(S)-4-methyl-2-phenylsulfonylaminovalerylamino]-2-tetrahydrofuranone 861 mg, which was reacted with hydrogendiisobutylaluminum to give (3S)-3-[(S)-4-Methyl-2-phenylsulfonylaminovalerylamino]-2-tetrahydrofuranol 191 mg, which showed strong calpain inhibition activity (I C50 0.62 μM).
IT 167765-43-7P 201155-39-7DP, salts, solvates, or hydrates
201155-39-7P 201155-40-0DP, salts, solvates, or hydrates
201155-40-0P 201155-41-1DP, salts, solvates, or hydrates
201155-41-1P 201155-42-2P 201155-44-4DP,
salts, solvates, or hydrates 201155-44-4P 201155-46-6P
201155-47-7DP, salts, solvates, or hydrates 201155-47-7P
201155-49-9P 201155-50-2P 201155-52-4DP,
salts, solvates, or hydrates 201155-52-4P 201155-54-6DP
, salts, solvates, or hydrates 201155-54-6P
201155-58-0DP, salts, solvates, or hydrates 201155-58-0P
201155-60-4DP, salts, solvates, or hydrates 201155-60-4P
201157-12-2DP, salts, solvates, or hydrates 201157-12-2P
201157-68-8P 207500-74-1P 207500-75-2P
207500-76-3DP, salts, solvates, or hydrates 207500-76-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cataract curative medicine)
RN 167765-43-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-39-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-39-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-40-0 CAPLUS
CN Pentadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-

furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-40-0 CAPLUS
CN Pentadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-41-1 CAPLUS
CN Hexadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-41-1 CAPLUS

CN Hexadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-42-2 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-2-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-44-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(hexadecylsulfonyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-44-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(hexadecylsulfonyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-46-6 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-4-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-47-7 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-47-7 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-49-9 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[[(4-methoxyphenyl)sulfonyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-50-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(2-naphthalenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-52-4 CAPLUS
CN Heptadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-52-4 CAPLUS
CN Heptadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-54-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tridecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-54-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tridecyl ester (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 201155-58-0 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(tetradecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-58-0 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(tetradecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-60-4 CAPLUS

CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(pentadecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-60-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(pentadecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-12-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(phenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-12-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(phenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-68-8 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[[(4-chlorophenyl)sulfonyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 207500-74-1 CAPLUS
CN Pentanamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[(2S,3S)-tetrahydro-2-(1-oxopropoxy)-3-furanyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 207500-75-2 CAPLUS
CN Pentanamide, 2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-4-methyl-N-[(2S,3S)-tetrahydro-2-(1-oxopropoxy)-3-furanyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 207500-76-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, heptadecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207500-76-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, heptadecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:102857 CAPLUS

DOCUMENT NUMBER: 128:167712
ORIGINAL REFERENCE NO.: 128:33065a,33068a
TITLE: Preparation of oxygenic heterocyclic derivatives of amino acid amides as cysteine protease inhibitors
INVENTOR(S): Ando, Ryoichi; Masuda, Hirokazu; Aritomo, Keiichi; Yoshii, Narihiko; Saito, Ken-Ichi
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804539	A1	19980205	WO 1997-JP2598	19970728 <--
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: JP 1996-199037 A 19960729 <--
OTHER SOURCE(S): MARPAT 128:167712
GI



AB Oxygenic heterocyclic derivs. of general formula [I; R1 = R4CO, R4O2C, R4SO2 (R4 = straight-chain C11-20 alkyl); R2 = C1-10 alkyl optionally substituted by C6-14 aryl; R3 = H, R5CO (wherein R5 = C1-10 alkyl); A = C1-3 alkylene optionally substituted by C1-3 alkyl], salts thereof, and solvates or hydrates thereof are prepared These compds. exhibit a potent inhibitory activity against cysteine proteases such as calpain, papain, cathepsin B, cathepsin H, cathepsin L, calpain, and interleukin 1β-converting enzyme and are excellent in absorbability through oral administration, tissue transportability, and cell membrane permeability and are useful for the treatment of muscular dystrophy, muscular atrophy, myocardial infarction, stroke, Alzheimer's disease, disorders of cognition and motor disorders in head trauma, multiple sclerosis, neuropathy of peripheral nerve, cataract, allergy, hepatitis siderans, osteoporosis, hypercalcemia, breast cancer, prostate cancer, prostatomegaly, inhibitors of cancer proliferation and metastasis, and blood platelet aggregation inhibitors. Thus, (3S)-3-[(S)-2-(tert-butoxycarbonylamino)-4-methylvalerylamino]-2-tetrahydrofuranone was stirred with 4 N HCl in EtOAc at room temperature for 45 min and then acylated by heptadecanoyl chloride in the presence of Et3N in CH2Cl2 at room temperature overnight to give (3S)-3-[(S)-2-(heptadecanoylamino)-4-methylvalerylamino]-2-tetrahydrofuranone, which was reduced by LiAlH4 in THF at -68° for 1 h to give (3S)-[(N-heptadecanoyl-L-leucinyl)amino]-2-tetrahydrofuranol (II; R = heptadecanoyl). The latter compound and II (R = pentadecylsulfonyl) in vitro showed IC50 of 1.05 and 0.09 μM, resp., against m-calpain.
IT 201155-39-7P 201155-40-0P 201155-41-1P

201155-44-4P 201155-52-4P 201155-54-6P
201155-56-8P 201155-58-0P 201155-60-4P
202814-98-0P 202815-01-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxygenic heterocyclic derivs. of amino acid amides as cysteine protease inhibitors for treatment of diseases)

RN 201155-39-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-40-0 CAPLUS
CN Pentadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-41-1 CAPLUS
CN Hexadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-44-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(hexadecylsulfonyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-52-4 CAPLUS
CN Heptadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-54-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tridecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-56-8 CAPLUS
CN Carbamic acid, [1-[[[2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, pentadecyl ester, [2S-[2α,3α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-58-0 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(tetradecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-60-4 CAPLUS

CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(pentadecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 202814-98-0 CAPLUS
CN Dodecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 202815-01-8 CAPLUS
CN Octadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:65808 CAPLUS
DOCUMENT NUMBER: 128:102004
ORIGINAL REFERENCE NO.: 128:19985a,19988a
TITLE: Preparation of hydroxytetrahydrofuran derivatives as remedies for ischemic diseases
INVENTOR(S): Yoshii, Narihiko; Saito, Ken-ichi; Kawasumi, Hisashi; Anabuki, Jun; Ando, Ryoichi
PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801130	A1	19980115	WO 1997-JP2378	19970709 <--
W: US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 10101558	A	19980421	JP 1997-179756	19970704 <--
EP 925786	A1	19990630	EP 1997-930735	19970709 <--
R: DE, ES, FR, GB, IT				

PRIORITY APPLN. INFO.:
JP 1996-180783 A 19960710 <--
JP 1996-207011 A 19960806 <--
WO 1997-JP2378 W 19970709 <--

OTHER SOURCE(S): MARPAT 128:102004
GI



I



II

AB The title compds. [I; R1 = R4CO, R4OCO, R4SO2, etc.; R2 = alkyl; R3 = H, acyl; R4 = (un)substituted C1-20 alkyl or C6-14 aryl, etc.; A = alkylene] are prepared I are efficacious in treating ischemic diseases, for example, ischemic brain diseases, cerebral stroke, cerebral thrombosis, cerebral embolism and myocardial infarction. Thus, compound (II; X = CO) (preparation

given) was reduced by (Me2CHCH2)2AlH to give 46% the title compound II (X = CHOH), which showed IC50 of 0.62 μM against calpain.

IT 167765-43-7P 201155-39-7P 201155-41-1P
201155-42-2P 201155-44-4P 201155-45-5P
201155-46-6P 201155-47-7P 201155-48-8P
201155-49-9P 201155-50-2P 201155-54-6P
201155-58-0P 201155-60-4P 201157-09-7P
201157-10-0P 201157-11-1P 201157-12-2P
201157-68-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxytetrahydrofuran derivs. as remedies for ischemic diseases)

RN 167765-43-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-39-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-41-1 CAPLUS

CN Hexadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-42-2 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-2-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-44-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(hexadecylsulfonyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-45-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (2S,3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(phenylsulfonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-46-6 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-4-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-47-7 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-48-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (2S,3S)-3-[[(2S)-2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-4-methyl-1-oxopentyl]amino]tetrahydro-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-49-9 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[[(4-methoxyphenyl)sulfonyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-50-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(2-naphthalenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-54-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tridecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-58-0 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(tetradecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-60-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(pentadecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-09-7 CAPLUS
CN Pentadecanamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-10-0 CAPLUS
CN Hexadecanamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-11-1 CAPLUS
CN Heptadecanamide, N-[(1S)-1-[[[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-12-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(phenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201157-68-8 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[[(4-chlorophenyl)sulfonyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:65807 CAPLUS
DOCUMENT NUMBER: 128:102386
ORIGINAL REFERENCE NO.: 128:20073a,20076a
TITLE: Preparation and formulation of amino acid derivatives for the prevention and treatment of neurodegenerative diseases
INVENTOR(S): Yoshii, Narihiko; Saito, Ken-ichi; Ando, Ryoichi
PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801129	A1	19980115	WO 1997-JP2377	19970709 <--
W: US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 10101560	A	19980421	JP 1997-179757	19970704 <--
PRIORITY APPLN. INFO.:			JP 1996-180784 A	19960710 <--

JP 1996-200757 A 19960730 <--
JP 1996-200758 A 19960730 <--
JP 1996-207012 A 19960806 <--

OTHER SOURCE(S): MARPAT 128:102386

GI



I

AB The title compds. I [R1 represents R4CO, etc.; R4 represents alkyl, aryl or cycloalkyl; R2 represents alkyl; R3 represents hydrogen or acyl; and A represents alkylene] are prepared These drugs are efficacious in preventing or treating neurodegenerative diseases, for example, Alzheimer's disease, diseases caused by demyelination in nerve cells, such as multiple sclerosis and neuropathy, and disorders accompanying cephalic traumas, such as consciousness disorder and motility disorder. (3S)-3-((S)-4-Methyl-2-phenylsulfonylaminovalerylamino)-2-tetrahydrofuranol in vitro showed IC50 of 0.62 μM against calpain.

IT 167765-43-7P 201155-15-9P 201155-39-7P
201155-40-0P 201155-41-1P 201155-42-2P
201155-43-3P 201155-44-4P 201155-45-5P
201155-46-6P 201155-47-7P 201155-48-8P
201155-49-9P 201155-50-2P 201155-52-4P
201155-54-6P 201155-56-8P 201155-58-0P
201155-60-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. for prevention and treatment of neurodegenerative diseases)

RN 167765-43-7 CAPLUS

CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-15-9 CAPLUS

CN Pentanamide, N-[(3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-

[(phenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-39-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-40-0 CAPLUS
CN Pentadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-41-1 CAPLUS
CN Hexadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-42-2 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-2-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-43-3 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-44-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[(hexadecylsulfonyl)amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-45-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (2S,3S)-tetrahydro-3-[[(2S)-4-methyl-1-oxo-2-[(phenylsulfonyl)amino]pentyl]amino]-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-46-6 CAPLUS
CN Benzamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-4-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-47-7 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-48-8 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (2S,3S)-3-[[(2S)-2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-4-methyl-1-oxopentyl]amino]tetrahydro-2-furanyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-49-9 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-2-[[(4-methoxyphenyl)sulfonyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-50-2 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(2-naphthalenylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-52-4 CAPLUS
CN Heptadecanamide, N-[(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-54-6 CAPLUS
CN Carbamic acid, [(1S)-1-[[[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, tridecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-56-8 CAPLUS
CN Carbamic acid, [1-[[[2-(acetyloxy)tetrahydro-3-furanyl]amino]carbonyl]-3-methylbutyl]-, pentadecyl ester, [2S-[2α,3α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-58-0 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(tetradecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 201155-60-4 CAPLUS
CN Pentanamide, N-[(2S,3S)-2-(acetyloxy)tetrahydro-3-furanyl]-4-methyl-2-[(pentadecylsulfonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil stng
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      68.36     254.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -8.20      -8.20

FILE 'STNGUIDE' ENTERED AT 14:14:43 ON 04 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 30, 2009 (20090130/UP).

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.75     256.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -8.20

STN INTERNATIONAL LOGOFF AT 14:29:48 ON 04 FEB 2009
```